Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
Laith J. Abu-Raddada,1, Lorenzo Sabatellia, Jerusha T. Achterberga,b,c, Jonathan D. Sugimotoa,b, Ira M. Longini, Jr.a,d, Christopher Dyee, and M. Elizabeth Hallorana,d,2
aVaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; Departments of bEpidemiology, cAnthropology, and dBiostatistics, University of Washington, Seattle, WA 98195; and eOffice of HIV/AIDS, Tuberculosis, Malaria, and Neglected Tropical Diseases, World Health Organization, CH-1211 Geneva 27, Switzerland Edited by Simon A. Levin, Princeton Universtiy, Princeton, NJ, and approved June 4, 2009 (received for review February 18, 2009)